TRAF3 and Its Biological Function

  • Jeannie Q. He
  • Gagik Oganesyan
  • Supriya K. Saha
  • Brian Zarnegar
  • Genhong Cheng
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 597)


Tumor necrosis factor receptor associated factor 3 (TRAF3) is one of the most enigmatic members in the TRAF family that consists of six members, TRAF1 to 6. Despite its similarities with other TRAFs in terms of structure and protein-protein association, overexpression of TRAF3 does not induce activation of the commonly known TRAF-inducible signaling pathways, namely NF-ºB and JNK. This lack of a simple functional assay in combination with the mysterious early lethality of the TRAF3-deficient mice has made the study of the biological function of TRAF3 challenging for almost ten years. Excitingly, TRAF3 has been identified recently to perform two seemingly distinct roles. Namely, TRAF3 functions as a negative regulator of the NF-κB pathway and separately, as a positive regulator of type I IFN production, placing itself as a critical regulator of both innate and adaptive immune responses.


Tumor Necrosis Factor Receptor Tumor Necrosis Factor Receptor Family Member 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104(4):487–501.PubMedCrossRefGoogle Scholar
  2. 2.
    Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor tumour necrosis factor receptor superfamily: Players, rules and the games. Immunology 2005; 115(1):1–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Rothe M, Wong SC, Henzel WJ et al. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994; 78(4):681–692.PubMedCrossRefGoogle Scholar
  4. 4.
    Hu HM, O’Rourke K, Boguski MS et al. A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem 1994; 269(48):30069–30072.PubMedGoogle Scholar
  5. 5.
    Sato T, Irie S, Reed JC. A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett 1995; 358(2):113–118.PubMedCrossRefGoogle Scholar
  6. 6.
    Cheng G, Cleary AM, Ye Z et al. Involvement of CRAF1, a Relative of TRAF, in CD40 Signaling. Science 1995; 267:1494–1498.PubMedCrossRefGoogle Scholar
  7. 7.
    Krajewski S, Zapata JM, Krajewska M et al. Immunohistochemical analysis of in vivo patterns of TRAF-3 expression, a member of the TNF receptor-associated factor family. J Immunol 1997; 159(12):5841–5852.PubMedGoogle Scholar
  8. 8.
    Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs)—a family of adapter proteins that regulates life and death. Genes Dev 1998; 12(18):2821–2830.PubMedGoogle Scholar
  9. 9.
    Chung JY, Park YC, Ye H et al. All TRAFs are not created equal: Common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002; 115(Pt 4):679–688.PubMedGoogle Scholar
  10. 10.
    Dempsey PW, Doyle SE, He JQ et al. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003; 14(3–4):193–209.PubMedCrossRefGoogle Scholar
  11. 11.
    Inoue J, Ishida T, Tsukamoto N et al. Tumor necrosis factor receptor-associated factor (TRAF) family: Adapter proteins that mediate cytokine signaling. Exp Cell Res 2000; 254(1):14–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Arch RH, Thompson CB. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 1998; 18(1):558–565.PubMedGoogle Scholar
  13. 13.
    Kawamata S, Hori T, Imura A et al. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2-and TRAF5-mediated NF-kappaB activation. J Biol Chem 1998; 273(10):5808–5814.PubMedCrossRefGoogle Scholar
  14. 14.
    Kwon B, Yu KY, Ni Y et al. Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem 1999; 274(10):6056–6061.PubMedCrossRefGoogle Scholar
  15. 15.
    Song HY, Regnier CH, Kirschning CJ et al. Tumor necrosis factor (TNF)-mediated kinase cascades: Bifurcation of nuclear factor-κB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci USA 1997; 94(18):9792–9796.PubMedCrossRefGoogle Scholar
  16. 16.
    Takeuchi M, Rothe M, Goeddel D. Anatomy of TRAF2. Distinct domains for nuclear factor-κB activation and association with tumor necrosis factor signaling proteins. J Biol Chem 1996; 271:19935–19942.PubMedCrossRefGoogle Scholar
  17. 17.
    Dadgostar H, Cheng G. An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-kappaB activation but is dispensable for c-Jun N-terminal kinase signaling. J Biol Chem 1998; 273(38):24775–24780.PubMedCrossRefGoogle Scholar
  18. 18.
    Dadgostar H, Cheng G. Membrane localization of TRAF 3 enables JNK activation. J Biol Chem 2000; 275:2539–2544.PubMedCrossRefGoogle Scholar
  19. 19.
    Hostager BS, Bishop GA. Cutting edge: Contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation. J Immunol 1999; 162(11):6307–6311.PubMedGoogle Scholar
  20. 20.
    Lee HH, Dempsey PW, Parks TP et al. Specificities of CD40 signaling: Involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation. Proc Natl Acad Sci USA 1999; 96(4):1421–1426.PubMedCrossRefGoogle Scholar
  21. 21.
    Xie P, Hostager BS, Bishop GA. Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes. J Exp Med 2004; 199(5):661–671.PubMedCrossRefGoogle Scholar
  22. 22.
    Floettmann JE, Rowe M. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappaB activation. Oncogene 1997; 15(15):1851–1858.PubMedCrossRefGoogle Scholar
  23. 23.
    Kieser A, Kaiser C, Hammerschmidt W. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J 1999; 18(9):2511–2521.PubMedCrossRefGoogle Scholar
  24. 24.
    Devergne O, Cahir McFarland ED, Mosialos G et al. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998; 72(10):7900–7908.PubMedGoogle Scholar
  25. 25.
    Brown KD, Hostager BS, Bishop GA. Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J Exp Med 2001; 193(8):943–954.PubMedCrossRefGoogle Scholar
  26. 26.
    Sandberg M, Hammerschmidt W, Sugden B. Characterization of LMP-1’s association with TRAF1, TRAF2, and TRAF3. J Virol 1997; 71(6):4649–4656.PubMedGoogle Scholar
  27. 27.
    Gedrich RW, Gilfillan MC, Duckett CS et al. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem 1996; 271(22):12852–12858.PubMedCrossRefGoogle Scholar
  28. 28.
    Marsters SA, Ayres TM, Skubatch M et al. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem 1997; 272(22):14029–14032.PubMedCrossRefGoogle Scholar
  29. 29.
    Park YC, Burkitt V, Villa AR et al. Structural basis for self-association and receptor recognition of human TRAF2. Nature 1999; 398(6727):533–538.PubMedCrossRefGoogle Scholar
  30. 30.
    Pullen SS, Miller HG, Everdeen DS et al. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: Regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 1998; 37(34):11836–11845.PubMedCrossRefGoogle Scholar
  31. 31.
    Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004; 16(6):801–807.PubMedCrossRefGoogle Scholar
  32. 32.
    McWhirter SM, Pullen SS, Holton JM et al. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc Natl Acad Sci USA 1999; 96(15):8408–8413.PubMedCrossRefGoogle Scholar
  33. 33.
    Ni CZ, Welsh K, Leo E et al. Molecular basis for CD40 signaling mediated by TRAF3. Proc Natl Acad Sci USA 2000; 97(19):10395–10399.PubMedCrossRefGoogle Scholar
  34. 34.
    Cheng G, Baltimore D. TANK, a coinducer with TRAF2 of TNF-and CD 40L-mediated NF-kappaB activation. Genes Dev 1996; 10(8):963–973.PubMedCrossRefGoogle Scholar
  35. 35.
    Dadgostar H, Doyle SE, Shahangian A et al. T3JAM, a novel protein that specifically interacts with TRAF3 and promotes the activation of JNK(1). FEBS Lett 2003; 553(3):403–407.PubMedCrossRefGoogle Scholar
  36. 36.
    Gamper C, van Eyndhoven WG, Schweiger E et al. TRAF-3 interacts with p62 nucleoporin, a component of the nuclear pore central plug that binds classical NLS-containing import complexes. Mol Immunol 2000; 37(1–2):73–84.PubMedCrossRefGoogle Scholar
  37. 37.
    Ha YJ, Lee JR. Role of TNF receptor-associated factor 3 in the CD40 signaling by production of reactive oxygen species through association with p40phox, a cytosolic subunit of nicotinamide adenine dinucleotide phosphate oxidase. J Immunol 2004; 172(1):231–239.PubMedGoogle Scholar
  38. 38.
    Hsu H, Huang J, Shu HB et al. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996; 4(4):387–396.PubMedCrossRefGoogle Scholar
  39. 39.
    Hu WH, Mo XM, Walters WM et al. TNAP, a novel repressor of NF-kappaB-inducing kinase, suppresses NF-kappaB activation. J Biol Chem 2004; 279(34):35975–35983.PubMedCrossRefGoogle Scholar
  40. 40.
    Ling L, Goeddel DV. MIP-T3, a novel protein linking tumor necrosis factor receptor-associated factor 3 to the microtubule network. J Biol Chem 2000; 275(31):23852–23860.PubMedCrossRefGoogle Scholar
  41. 41.
    Meylan E, Martinon F, Thome M et al. RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF-kappa B and is processed during apoptosis. EMBO Rep 2002; 3(12):1201–1208.PubMedCrossRefGoogle Scholar
  42. 42.
    Nishitoh H, Saitoh M, Mochida Y et al. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 1998; 2(3):389–395.PubMedCrossRefGoogle Scholar
  43. 43.
    Pype S, Declercq W, Ibrahimi A et al. TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa B activation. J Biol Chem 2000; 275(24):18586–18593.PubMedCrossRefGoogle Scholar
  44. 44.
    Qian Y, Zhao Z, Jiang Z et al. Role of NF-κB activator Act1 in CD40-mediated signaling in epithelial cells. Proc Natl Acad Sci USA 2002; 99(14):9386–9391.PubMedCrossRefGoogle Scholar
  45. 45.
    Rothe M, Xiong J, Shu HB et al. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Proc Natl Acad Sci USA 1996; 93(16):8241–8246.PubMedCrossRefGoogle Scholar
  46. 46.
    Wong BR, Besser D, Kim N et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Molecular Cell 1999; 4(6):1041–1049.PubMedCrossRefGoogle Scholar
  47. 47.
    Hostager BS, Catlett IM, Bishop GA. Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J Biol Chem 2000; 275(20):15392–15398.PubMedCrossRefGoogle Scholar
  48. 48.
    Xu Y, Cheng G, Baltimore D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 1996; 5:407–415.PubMedCrossRefGoogle Scholar
  49. 49.
    Baeuerle PA, Baltimore D. NF-kappa B: Ten years after. Cell 1996; 87(1):13–20.PubMedCrossRefGoogle Scholar
  50. 50.
    Kopp EB, Ghosh S. NF-kappa B and rel proteins in innate immunity. Adv Immunol 1995; 58:1–27.PubMedCrossRefGoogle Scholar
  51. 51.
    Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18:621–663.PubMedCrossRefGoogle Scholar
  52. 52.
    Zandi E, Karin M. Bridging the gap: Composition, regulation, and physiological function of the IkappaB kinase complex. Mol Cell Biol 1999; 19(7):4547–4551.PubMedGoogle Scholar
  53. 53.
    Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18(18):2195–2224.PubMedCrossRefGoogle Scholar
  54. 54.
    Sizemore N, Lerner N, Dombrowski N et al. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 2002; 277(6):3863–3869.PubMedCrossRefGoogle Scholar
  55. 55.
    Matsushima A, Kaisho T, Rennert PD el al. Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I. J Exp Med 2001; 193(5):631–636.PubMedCrossRefGoogle Scholar
  56. 56.
    Yin L, Wu L, Wesche H el al. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science 2001; 291(5511):2162–2165.PubMedCrossRefGoogle Scholar
  57. 57.
    Xiao G, Fong A, Sun SC. Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem 2004; 279(29):30099–30105.PubMedCrossRefGoogle Scholar
  58. 58.
    Scheinman RI, Beg AA, Baldwing AS. NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule. Mol Cell Biol 1993; 13(10):6089–6101.PubMedGoogle Scholar
  59. 59.
    Dejardin E, Droin NM, Delhase M el al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17(4):525–535.PubMedCrossRefGoogle Scholar
  60. 60.
    Hoffmann A, Levchenko A, Scott ML et al. The IkappaB-NF-kappaB signaling module: Temporal control and selective gene activation. Science 2002; 298(5596):1241–1245.PubMedCrossRefGoogle Scholar
  61. 61.
    Claudio E, Brown K, Park S el al. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 2002; 3(10):958–965.PubMedCrossRefGoogle Scholar
  62. 62.
    Caamano JH, Rizzo CA, Durham SK et al. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med 1998; 187(2):185–196.PubMedCrossRefGoogle Scholar
  63. 63.
    Yilmaz ZB, Weih DS, Sivakumar V et al. RelB is required for Peyer’s patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J 2003; 22(1):121–130.PubMedCrossRefGoogle Scholar
  64. 64.
    Coope HJ, Atkinson PG, Huhse B et al. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002; 21(20):5375–5385.PubMedCrossRefGoogle Scholar
  65. 65.
    Kawabe T, Naka T, Yoshida K et al. The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation. Immunity 1994; 1(3):167–178.PubMedCrossRefGoogle Scholar
  66. 66.
    Rennert PD, James D, Mackay F et al. Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity 1998; 9(1):71–79.PubMedCrossRefGoogle Scholar
  67. 67.
    Schiemann B, Gommerman JL, Vora K et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293(5537):2111–2114.PubMedCrossRefGoogle Scholar
  68. 68.
    Liao G, Zhang M, Harhaj EW et al. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004; 279(25):26243–26250.PubMedCrossRefGoogle Scholar
  69. 69.
    Hauer J, Puschner S, Ramakrishnan P et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 2005; 102(8):2874–2879.PubMedCrossRefGoogle Scholar
  70. 70.
    Hostager BS, Haxhinasto SA, Rowland SL et al. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem 2003; 278(46):45382–45390.PubMedCrossRefGoogle Scholar
  71. 71.
    Grech AP, Amesbury M, Chan T et al. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004; 21(5):629–642.PubMedCrossRefGoogle Scholar
  72. 72.
    Sun L, Deng L, Ea CK et al. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004; 14(3):289–301.PubMedCrossRefGoogle Scholar
  73. 73.
    Beg AA, Sha WC, Bronson RT et al. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev 1995; 9(22):2736–2746.PubMedCrossRefGoogle Scholar
  74. 74.
    Ishikawa H, Carrasco D, Claudio E et al. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappa B2. J Exp Med 1997; 186(7):999–1014.PubMedCrossRefGoogle Scholar
  75. 75.
    Oganesyan G, Saha SK, Guo B et al. Critical role of TRAF3 in the Toll-like receptor-dependent and-independent antiviral response. Nature 2006: 439(7073):208–211.PubMedCrossRefGoogle Scholar
  76. 76.
    Theofilopoulos AN, Baccala R, Beutler B et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23:307–336.PubMedCrossRefGoogle Scholar
  77. 77.
    Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol Immunol 2005; 42(8):859–867.PubMedCrossRefGoogle Scholar
  78. 78.
    Kawai T, Akira S. TLR signaling. Cell Death Differ 2006.Google Scholar
  79. 79.
    Jiang Z, Mak TW, Sen G et al. Toll-like receptor 3 mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci USA 2004; 101(10):3533–3538.PubMedCrossRefGoogle Scholar
  80. 80.
    Chariot A, Leonardi A, Muller J et al. Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases J Biol Chem 2002; 277(40):37029–37036.PubMedCrossRefGoogle Scholar
  81. 81.
    Pomerantz JL, Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J 1999; 18(23):6694–6704.PubMedCrossRefGoogle Scholar
  82. 82.
    Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 2004; 24(8):439–454.PubMedCrossRefGoogle Scholar
  83. 83.
    Hemmi H, Takeuchi O, Sato S et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 2004; 199(12):1641–1650.PubMedCrossRefGoogle Scholar
  84. 84.
    Perry AK, Chow EK, Goodnough JB et al. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med 2004; 199(12):1651–1658.PubMedCrossRefGoogle Scholar
  85. 85.
    Coccia EM, Severa M, Giacomini E et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34(3):796–805.PubMedCrossRefGoogle Scholar
  86. 86.
    Colonna M, Krug A, Cella M. Interferon-producing cells: On the front line in immune responses against pathogens. Curr Opin Immunol 2002; 14(3):373–379.PubMedCrossRefGoogle Scholar
  87. 87.
    Diebold SS, Kaisho T, Hemmi H et al. Innate antivital responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303(5663):1529–1531.PubMedCrossRefGoogle Scholar
  88. 88.
    Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303(5663):1526–1529.PubMedCrossRefGoogle Scholar
  89. 89.
    Krug A, Luker GD, Barchet W et al. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 2004; 103(4):1433–1437.PubMedCrossRefGoogle Scholar
  90. 90.
    Kawai T, Takahashi K, Sato S et al. IPS-1, an adaptor triggering RIG-I-and Mda5-mediated type I interferon induction. Nat Immunol 2005; 6(10):981–988.PubMedCrossRefGoogle Scholar
  91. 91.
    Meylan E, Curran J, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437(7062):1167–1172.PubMedCrossRefGoogle Scholar
  92. 92.
    Seth RB, Sun L, Ea CK et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005; 122(5):669–682.PubMedCrossRefGoogle Scholar
  93. 93.
    Xu LG, Wang YY, Han KJ et al. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005; 19(6):727–740.PubMedCrossRefGoogle Scholar
  94. 94.
    Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005; 7(8):758–765.PubMedCrossRefGoogle Scholar
  95. 95.
    Mercurio F, Zhu H, Murray BW et al. IKK-1 and IKK-2: Cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 1997; 278(5339):860–866.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2007

Authors and Affiliations

  • Jeannie Q. He
  • Gagik Oganesyan
  • Supriya K. Saha
  • Brian Zarnegar
  • Genhong Cheng
    • 1
  1. 1.Department of Microbiology, Immunology and Molecular GeneticsUniversity of California, Los AngelesLos AngelesUSA

Personalised recommendations